Trial Profile

A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 18 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs QR-1123 (Primary)
Indications Retinitis pigmentosa
Focus Adverse reactions; First in man; Proof of concept
Acronyms AURORA
Sponsors ProQR Therapeutics

Most Recent Events

05 May 2022 Planned End Date changed from 1 Jul 2022 to 7 Jun 2022.
05 May 2022 Planned primary completion date changed from 1 Jul 2022 to 7 Jun 2022.
05 May 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com